J F R Robertson
Overview
Explore the profile of J F R Robertson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1503
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Young B, Bedford L, Kendrick D, Vedhara K, Robertson J, das Nair R
J Public Health (Oxf)
. 2017 May;
40(2):315-339.
PMID: 28486650
Background: This review aimed to better understand experiences of being invited to cancer screening and associated decision-making. Methods: Qualitative evidence explaining UK cancer screening attendance decisions was systematically identified. Data...
2.
Robertson J, Herrod P, Matthew J, Kilburn L, Coles C, Bradbury I
Crit Rev Oncol Hematol
. 2017 Jan;
110:74-80.
PMID: 28109407
Invasive breast cancer is the second most common cancer worldwide. It is known to metastasise to the regional axillary lymph nodes but there has been debate over what is the...
3.
Mathew J, Karia R, Morgan D, Lee A, Ellis I, Robertson J, et al.
Breast
. 2016 Nov;
31:181-185.
PMID: 27871025
Background: The aim of our study was to assess various predictors for local recurrence (LR) in patients undergoing breast conservation surgery (BCS) for ductal carcinoma in situ (DCIS). Materials And...
4.
Mathew J, Prinsloo P, Agrawal A, Gutteridge E, Marenah C, Robertson J, et al.
Breast
. 2014 May;
23(5):567-72.
PMID: 24874285
Background: This pilot study aimed to test the possibility of therapeutic benefit imparted by early intervention based on sequential tumour marker (TM) measurements during follow-up of primary breast cancer (PBC)...
5.
Jonat W, Bachelot T, Ruhstaller T, Kuss I, Reimann U, Robertson J
Ann Oncol
. 2013 Jun;
24(10):2543-2548.
PMID: 23788750
Background: The progesterone-receptor (PR) antagonists onapristone (type I) and mifepristone (type II) showed modest activity in hormone-receptor-positive breast cancer; however, onapristone in particular was associated with hepatotoxicity. Lonaprisan is a...
6.
Johnston S, Kenny F, Syed B, Robertson J, Pinder S, Winterbottom L, et al.
Ann Oncol
. 2012 Feb;
23(9):2296-2300.
PMID: 22357257
Background: Long-term analysis of a randomised trial in Nottingham comparing tamoxifen versus surgery as initial treatment demonstrated that in oestrogen receptor (ER)-unselected cases, surgery achieved better local control, with no...
7.
Barrios C, Forbes J, Jonat W, Conte P, Gradishar W, Buzdar A, et al.
Ann Oncol
. 2012 Feb;
23(6):1378-86.
PMID: 22317766
Background: Hormone receptor-positive advanced breast cancer is an increasing health burden. Although endocrine therapies are recognised as the most beneficial treatments for patients with hormone receptor-positive advanced breast cancer, the...
8.
Cheung K, Agrawal A, Folkerd E, Dowsett M, Robertson J, Winterbottom L
Eur J Cancer
. 2010 Sep;
46(16):2936-42.
PMID: 20832294
Trials have shown superiority of aromatase inhibitors (AIs) over tamoxifen for post-menopausal oestrogen receptor-positive advanced breast cancer (ER+ABC). We previously reported the use of goserelin plus anastrozole (G+A) as second-line...
9.
Boyle P, Chapman C, Holdenrieder S, Murray A, Robertson C, Wood W, et al.
Ann Oncol
. 2010 Aug;
22(2):383-9.
PMID: 20675559
Background: Autoantibodies may be present in a variety of underlying cancers several years before tumours can be detected and testing for their presence may allow earlier diagnosis. We report the...
10.
Chakrabarti J, Kenny F, Syed B, Robertson J, Blamey R, Cheung K
Crit Rev Oncol Hematol
. 2010 May;
78(3):260-4.
PMID: 20447833
A recent Cochrane review of trials involving elderly women with operable primary breast cancer showed no significant difference in overall survival between surgery (±adjuvant tamoxifen) and primary endocrine therapy using...